EMERYVILLE, CA, Oct. 8 /CNW/ - KineMed Inc., a privately held
pathway-based drug discovery and development company announced today that
David M. Fineman, CEO and President of KineMed, will present an overview of
the company and its drug development programs at the 4th Annual BIO Investor
Forum in San Francisco on Thursday, October 11 at 2:00 p.m. PDT in the Pacific
Heights room of the Palace Hotel. Mr. Fineman will provide an update on the
company's lead discovery and development programs centered on cardio-metabolic
disorders including atherosclerosis, and diabetes and dyslipidemia. Mr.
Fineman will also discuss KineMed's internal drug development program in ALS
and provide an overview on the company's partnering and collaboration efforts,
including KineMed's clinical development collaborations with Merck & Co., Inc.
and Merck KGaA to advance drugs that increase reverse cholesterol transport.
KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and
development company employing its proprietary translational medicine
technology (AquaTag(TM) and KineMarker(TM)) to both identify active drug
candidates preclinically and confirm their therapeutic activity and dose
response in first-in-man studies. KineMed's technology expedites the drug
development process and provides real-time insight into conditions including
metabolic disorders, cancer, and diseases of inflammation and
neurodegeneration. KineMed is working to develop drugs both on its own and
with pharmaceutical collaborators in therapeutic focus areas where it can
demonstrate functional modulation of specific biological pathways that mediate
disease. The Company has multiple development programs with more than a dozen
major pharmaceutical companies, including Bayer, Merck & Co., Inc., Merck
KGaA, Organon and Roche.
For further information about KineMed, please visit:
Brent Vaughan, Chief Business Officer of KineMed Inc., +1-510-655-6525,
Justin Jackson of Burns McClellan, firstname.lastname@example.org
John Cummings, email@example.com, both of Burns McClellan,
+1-212-213-0006, both for KineMed Inc.
For further information:
For further information: Brent Vaughan, Chief Business Officer of
KineMed Inc., (510) 655-6525, ext. 110; Media, Justin Jackson of Burns
McClellan, firstname.lastname@example.org, or Investors, John Cummings,
email@example.com, both of Burns McClellan, (212) 213-0006, both for
KineMed Inc., Web Site: http://www.kinemed.com